Virbac account plan
Animal health solutions worldwide
At a glance
Virbac is a French animal health company making veterinary medicines, vaccines and petfood, with 2025 revenue of €1,464.7 million.
Virbac is 100% dedicated to animal health and ranks 6th worldwide among veterinary drug manufacturers. It develops, produces and distributes pharmaceuticals, vaccines, nutraceuticals, hygiene products and specialized petfood for companion and farm animals, sold mainly through wholesalers and purchasing groups that supply veterinarians. In 2025 it reported revenue of €1,464.7 million (+7.9% at constant rates and scope), adjusted EBIT of €234.4 million (16.0%) and net profit Group share of €150.9 million. It had 6,442 employees in 37 countries at end-2025, with production sites in 12 countries. The Dick family group holds 50.09% of the capital and 66.21% of voting rights.
Business units
Companion animals
59.3% of 2025 revenue (€869.2 million); 60.3% of H1 2026 revenueSpecialties, specialized petfood, antibiotics/dermatology, parasiticides, immunology and equine products for pets. It grew 10.9% at constant rates and scope in 2025 and 10.0% in H1 2026, led by petfood, specialties and the Thyronorm endocrinology range; Virbac targets petfood revenue above €200 million in 2035.
Farm animals
39.3% of 2025 revenue (€575.2 million); 38.9% of H1 2026 revenueRuminant nutritionals, vaccines, antibiotics and parasiticides, plus pig, poultry and aquaculture products. It grew 6.8% in 2025 and 6.7% in H1 2026, driven by ruminants and the bluetongue response in Europe, while aquaculture in Chile faced competitive pressure.
Other businesses
1.4% of 2025 revenue (€20.3 million)Industrial processing for third parties in Australia and the United States, including Sentinel Spectrum sales to MSD Animal Health. Revenue fell 42.2% in 2025 and 53.6% in H1 2026.
Strategic priorities
- Supercharge growth platforms
- Under the 'Growing Together' strategy, Virbac focuses on petfood, reproduction, dental, mobility, ear, endocrinology and ruminants; these platforms grew around 12% in H1 2026.
- Margin toward around 20%
- Virbac committed to move profitability to around 20% and guides an adjusted EBIT margin around 17% for 2026, with revenue growth at the upper end of its 5.5%-7.5% range.
- Record R&D
- R&D investment was a record €115 million in 2025, 8.7% of revenue, and management plans to increase the share of R&D in revenue.
- US scale
- The US is described as an absolute priority, and adding scale there is priority #1 for M&A; nearly 80% of US revenue is expected to come from local US production by end-2026.
- Omnichannel and direct-to-consumer
- Virbac is increasing advertising and promotion as part of the business shifts toward an omnichannel model, partly direct-to-consumer.
Latest results
H1 2026 revenue was €768.0 million, +7.4% at constant exchange rates and +4.0% at actual rates, with growth from volume and mix (about 5.4%) and price (about 2%). Adjusted EBIT rose to €144.2 million, 18.8% of revenue, and net profit Group share to €87.4 million. By region, Europe grew 6.5%, North America 10.1% and International 7.5%. Net debt rose to €195.9 million on seasonal working capital and capex. Virbac now targets the upper end of its 5.5%-7.5% growth guidance, an adjusted EBIT margin around 17% and capex around €125 million.
Investments and deals
- Industrial transformation programme
- Over €100 million committed to modernize facilities, including a new companion animal vaccine plant in the south of France, a new Suprelorin line, a new petfood plant and a new logistics center; capex around €125 million is guided for 2026.
- Thyronorm acquisition
- Feline hyperthyroidism treatment acquired in December 2025 from Norbrook, adding about 1 point of 2026 revenue growth; most of Europe comes under direct Virbac management in 2027.
- Licensing deals
- Porus One and Vetcare licensing deals signed in H1 2026, distributed from 2027 with options for full acquisition.
- Quality and digital
- €23 million of Quality investments in 2025 and around €25 million of quality upgrades at key sites planned for 2026, alongside record digital and IT investment.
Challenges and risks
- Currency headwinds
- Currency cut €25 million from H1 2026 revenue, mainly through emerging-market currencies such as the Mexican peso, Brazilian real and Indian rupee.
- Supply constraints
- France and Belgium were flat in H1 2026 mainly due to supply constraints, and North America faced temporary regulatory hurdles in toll manufacturing and farm animal supply constraints.
- Competition and distribution consolidation
- Virbac competes with larger players and faces consolidation of distributors and vet clinic networks; Australia saw intense competition in H1 2026.
- Hard-to-hire talent
- Skills in industry, quality assurance and R&D are hard to hire, notably in France.
- Trade and input costs
- Active ingredients are sourced from Asia, direct US customs duties are estimated at approximately US $3 million a year, and the Middle East crisis brought oil-driven inflation.
What leadership says
“committed to deliver our 2026 goals while shaping our future through industrial and digital strategic transformation projects and record levels of investments in R&D.”
“because we believe clearly that in our industry, it's all about innovation”
“We're not managing a share price.”
Where a supplier can help
- Plant construction and equipment
- Tied to the industrial transformation programme: a new vaccine plant, petfood plant and logistics center, with capex expected above €100 million for a few years, open room for engineering, equipment and automation suppliers.
- Quality and supply-chain reliability
- Tied to the supply constraints challenge and quality investments: offers that improve GMP quality, planning and capacity at constrained sites address issues named in the H1 2026 report.
- Omnichannel marketing and DTC
- Tied to the omnichannel priority: higher advertising and promotion spend and a partly direct-to-consumer model call for marketing, e-commerce and customer data capabilities.
- Recruiting in technical roles
- Tied to the hard-to-hire talent challenge in industry, quality assurance and R&D, notably in France.
- Digital and IT transformation
- Tied to the record digital and IT investment the CEO describes alongside the industrial projects.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Virbac?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report 2025
- Virbac is a French animal health group, 100% dedicated to animal health for nearly 60 years, ranked 6th worldwide among veterinary drug manufacturers, with 6,442 employees in 37 countries at end-2025, sales subsidiaries in 36 countries and production sites in 12 countries.
- 2025 revenue reached €1,465 million (€1,464.7 million), +4.8% at actual rates and +7.9% at constant exchange rates and scope; the Sasaeah acquisition (Japan, April 2024) added 0.8 points.
- Companion animals were 59.3% of revenue (€869.2 million, +10.9%), driven by specialized petfood (+18.7%), specialties (+16.7%) and antibiotics/dermatology (+8.1%); farm animals were 39.3% (€575.2 million, +6.8%), driven by ruminants.
- North America grew +14.7% at constant rates (companion animals +24.2%, launches Ursolyx and Zenifel); Europe +7.5%, IMEA +9.5%, Latin America +7.4%, Far East Asia +3.3%, Pacific +0.1%.
- Adjusted EBIT (current operating profit before amortization of acquired intangibles) was €234.4 million, 16.0% of revenue (16.3% at constant rates); net profit Group share €150.9 million (2024: €145.3 million); net debt €172.8 million.
- Record R&D investment of €115 million (8.7% of revenue spent on research, development and licensing); over €100 million committed to modernizing facilities (new vaccine plant, Suprelorin line, petfood plant, logistics center); €23 million invested in Quality.
- December 2025 acquisition of the company holding the rights to Thyronorm (feline hyperthyroidism, about €15 million annual revenue), sold as Felanorm in the US; goodwill of €112.4 million recognized.
- 2026 outlook: revenue growth of 5.5% to 7.5% at constant rates and scope, adjusted EBIT margin around 17%, cash generation around €80 million, capex about €125 million; direct US tariff impact estimated at about US $3 million.
- Paul Martingell became CEO on September 1, 2025; Habib Ramdani returned to CFO and deputy CEO; the Dick family group holds 50.09% of the capital and 66.21% of voting rights.
- Half-yearly financial report as of June 30, 2026
- H1 2026 revenue was €768.0 million, +4.0% at actual rates and +7.4% at constant exchange rates and scope; volume and mix added about 5.4% and price about 2%.
- Companion animals were 60.3% of revenue (€463.2 million, +10.0%), led by specialties (+23.4%, including Thyronorm) and specialized petfood (+13.7%); parasiticides fell 5.5%.
- Farm animals were 38.9% of revenue (€298.5 million, +6.7%), led by other ruminant products (+15.0%: nutritionals, vaccines).
- New regional structure in three segments: Europe +6.5%, North America +10.1%, International +7.5% (IMEA and Latin America double-digit; Pacific weak on Australian competition).
- Adjusted EBIT rose to €144.2 million, 18.8% of revenue (H1 2025: 18.3%), on a one-point gross margin gain (68.4%); net profit Group share €87.4 million (+6.0%).
- Net debt €195.9 million at June 30, 2026, up €23.1 million on seasonal working capital and capex; €40 million of new seven-year credit lines finance a new companion animal vaccine plant.
- 'Supercharge' platforms (petfood, reproduction, dental, mobility, ear, endocrinology, ruminants) are the main growth drivers.
- 2026 guidance: now targeting the upper end of 5.5%-7.5% growth; adjusted EBIT margin around 17%, cash generation around €80 million, capex around €125 million.
- A €5.0 million option was paid for the potential acquisition of a company, conditional on regulatory approval of a product.
- Exclusive: Virbac's New CEO on Investment, Innovation & Long-Term Growth Strategy (Animal Health Insider)
- Paul Martingell, CEO since September 2025 and new to animal health (from consumer health and pharmaceuticals), gave his first in-depth industry interview to Animal Health Insider about 200 days into the role.
- He frames 2026 as "a time of investment, a time of growth": record R&D, record capex, record quality spending and record digital and IT investment despite geopolitical uncertainty.
- Major projects: a new companion animal vaccine plant in the south of France (a hundred million euros plus), a new logistics and distribution center, and about €25 million of quality upgrades in 2026.
- He says the family's controlling stake allows long-term decisions: "We're not managing a share price."
- Acquisitions are "a core part of our business model"; Thyronorm/Felanorm was chosen for growing cat populations, longer lives and a liquid, palatable format.
- Virbac is on track for its 2030 commitment of around 20% profitability, with around 17% guided for 2026 and growth of 5.5% to 7.5%, which he expects to beat the market.
- Growth priority: re-energizing under-used innovations, e.g. non-surgical castration (under 1% of castrations) and Vikaly, the first medicated pet food (around 15 years of work).
- Culture: curiosity, customer obsession, "small enough to truly care", more performance focus, regional leaders added to the leadership team.
- Virbac H1 2026 results call transcript
- Results call for H1 2026 (September 18, 2026) with CEO Paul Martingell and CFO and deputy CEO Habib Ramdani.
- H1 growth of 7.4% at constant rates (5% volume, 2% price), with Thyronorm adding 1.4 points; Supercharge platforms grew around 12%; adjusted EBIT margin 18.8%, up 50 basis points.
- North America and the International region grew double-digit, including India and Latin America; Pacific had headwinds; the market is robust despite a slowdown in US companion animals.
- Thyronorm integration is ahead of expectations; most of Europe moves to direct Virbac distribution in 2027.
- Two licensing deals (Porus One, Vetcare) with options to acquire, worth "low double-digit million" in revenue from 2027; US scale is "absolutely priority #1" for M&A.
- Leverage: comfortable around 2x net debt/EBITDA, possibly 2.5x; no share buyback, external growth preferred.
- Capex will stay above €100 million for a few years; 2026 guidance: upper end of 5.5%-7.5%, EBIT adjusted around 17%, capex around €125 million, cash around €80 million.
- Net cash flow around €130 million in H1, free cash flow -€7 million, net debt/EBITDA 0.6.
Questions about Virbac
What does Virbac do?
Virbac develops, produces and distributes veterinary medicines, vaccines, nutraceuticals, hygiene products and specialized petfood for companion and farm animals, sold mainly to veterinarians through wholesalers.
What is Virbac's revenue?
Revenue was €1,464.7 million in 2025, with adjusted EBIT of €234.4 million. H1 2026 revenue was €768.0 million, +7.4% at constant exchange rates.
How many employees does Virbac have?
Virbac had 6,442 employees in 37 countries at end-2025, 25.1% of them in France.
Who leads Virbac?
Paul Martingell has been CEO since September 2025; Habib Ramdani is CFO and deputy CEO, and Marie-Hélène Dick-Madelpuech chairs the board.
What is Virbac's strategy?
Grow above its market through the Supercharge platforms, invest record amounts in R&D and plants, expand through acquisitions with US scale as priority, and lift profitability toward around 20%.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)